How is Medicinal Cannabis Used? A Guide to Delivery Methods in NZ

Executive summary

Medicinal cannabis in New Zealand is not one single product and it is not used in one single way. It can be prescribed in different forms, including oils or oral liquids, sprays, dried flower for vaporisation, dried flower for tea, capsules, and in some situations other unapproved formulations that a doctor may decide to use for a particular patient. ^1,2,3

The route matters because it changes how quickly a product takes effect, how long it tends to last, how practical it is in daily life, and what needs to be monitored. Oral routes are usually slower and more variable. Vaporisation is faster. Tea is an oral route in its own right and only applies when a dried flower product is verified for tea preparation. ^2,3

In practice, clinicians are not choosing between products based on a marketing label or a strain name. They are usually thinking about formulation, route, THC and CBD content, possible terpene profile, medicine interactions, driving and workplace implications, and whether the person can actually use that form safely and consistently. ^{1,2,3,6,7,11,12}

That is why the most useful patient question is rarely “Which product is best?” It is usually “Which form makes sense for my situation, and why?” ^1,2,3

Medically Reviewed by Dr. William Parkyn

Start with the basics

If you are new to medicinal cannabis, the number of delivery methods can be confusing.

People often come in expecting there to be one standard format. There is not. New Zealand’s medicinal cannabis framework includes dried cannabis material and pharmaceutical dosage forms, and the Ministry of Health makes it clear that products are verified against minimum quality standards according to dosage form and route. ^1,2

That means the same broad ingredient can behave very differently depending on how it is used. A swallowed oil, an oral spray, flower for vaporisation, and flower for tea are not interchangeable just because they all contain cannabis-derived ingredients. ^2,3

Why delivery method matters

Delivery method affects four practical things.

The first is onset. Some routes reach effect quickly, while others come on more gradually. ³

The second is duration. Some routes are shorter-acting, while others tend to last longer. ³

The third is predictability. Swallowed products tend to be more variable because digestion and first-pass metabolism play a role. Vaporised products usually act faster, but they also bring different practical considerations. ^3,8

The fourth is fit. A route that looks good on paper may not suit someone’s workday, their comfort with inhaled products, their other medicines, or their ability to follow the preparation steps involved. ^1,2,3

The main delivery methods used in New Zealand

Oils and oral liquids

Oils and oral liquids are one of the most familiar formats for patients.

They are swallowed, so they sit in the oral route category. In New Zealand, the Ministry notes that medicinal cannabis products may be available in liquid form, particularly CBD products, and bpacnz groups oral liquid with other oral forms such as capsules and tea. ^1,3

The trade-off is that oral administration is the slowest and most variable route. bpacnz notes that oral cannabis products have relatively low bioavailability because of intestinal and hepatic first-pass metabolism, with effects usually building progressively, peaking after two to four hours, and lasting anywhere from 6 to 24 hours. ³

That longer duration can be useful in some clinical plans, but it also means patients and prescribers need to be careful about timing, accumulation, and how the route fits with work, driving, childcare, or evening routines. ^3,8

Oromucosal sprays

Oromucosal sprays are designed for use in the mouth rather than as a fully swallowed product.

bpacnz notes that this route may allow some direct absorption through the oral mucosa, even though some of the product is still swallowed. Effects are described as peaking at roughly 90 to 120 minutes and lasting for a timeframe similar to oral products. ³

For some people, sprays can feel more convenient than measuring an oil. For others, the practical difference is small. What matters clinically is that this is still a distinct route with its own absorption pattern and not simply “an oil in a different bottle”. ³

Dried flower for vaporisation

New Zealand’s medicinal cannabis system allows for dried flower products that are verified for inhalation via a vaporiser. ²

This is where legal and clinical detail matters. The Ministry states that a person may be prescribed medicinal cannabis in a dried form for use through a medical vaporiser. It also notes that the route is specifically vaporisation, not smoking. ¹

bpacnz describes vaporisation as the fastest route, with peak plasma concentrations within minutes, effects reaching a maximum after around 15 to 30 minutes, and typical duration of 2 to 4 hours. ³ That faster onset can make a real difference in how the route is used in practice.

It also comes with practical issues. The Ministry says only certain medical-device-approved vaporisers can be imported lawfully, and non-approved devices with prohibited features may be confiscated by Customs. ¹ In daily life, inhaled routes may also be less convenient in some workplaces or public settings, even before you get to questions about smell, privacy, or timing. ^1,3 Inhalation also comes with potential risks of respiratory harm, that oral ingestion avoids. ^3,9

Dried flower for tea

Tea is a separate route, not just an alternative way of using any dried flower.

The Ministry’s medicinal cannabis product page has a distinct category for dried cannabis flower for preparing tea for oral consumption. It also states clearly that these products do not meet the minimum quality standard for inhalation. ²

That matters because route-specific verification is a core part of the NZ framework. If flower is verified for tea, that does not mean it is automatically appropriate for vaporisation, and vice versa. ^2,3

Tea sits with the oral routes. That means it tends to behave more like other swallowed forms than like a vaporised flower. BPACNZ groups tea alongside oral liquid and capsules as the slowest and most variable route, again because digestion and first-pass metabolism affect exposure. ^3,9

The Ministry also provides generic preparation instructions for dried cannabis flower tea on its minimum quality standard page. Those instructions are the official source patients should use, alongside any specific advice from their prescriber or dispensing pharmacy. ²

Topicals

Topicals are the category many people ask about but often understand least.

In the international literature, this can include creams, gels, and transdermal-style products. BPACNZ notes that most topical formulations produced overseas are CBD-based, and that onset and duration are hard to predict and may vary substantially between patients. ³

That uncertainty is part of the reason topicals should be trialed with medical oversight. Some people find them very effective, and some do not. CBD topicals, such as those the Cannabis Clinic can offer generally have very few systemic side effects and so clinicians are often happy for them to be trialed. ¹⁰

What about transdermal patches?

Transdermal patches are worth mentioning because they do exist internationally in the literature.

They are usually discussed as a way to avoid the variability of the digestive route while also avoiding inhalation. Reviews of skin-applied cannabinoid products describe ongoing research interest in both topical and transdermal delivery, but they also make clear that the evidence base is still developing. ¹⁰

In New Zealand, transdermal patches are not currently listed as a verified dosage form on the Ministry’s medicinal cannabis schedule and the clinic does not import them. ² So while the format exists internationally, its current availability in New Zealand is unspecified and not part of the mainstream verified forms currently listed by the Ministry. ^2,10

Why formulation matters more than strain names

If you spend time reading online forums, you will see a lot of focus on strain names.

In clinical care, that is not usually the most useful way to think about medicinal cannabis. The better questions are about formulation, route, and composition.

That includes:

• whether the product is an oil, spray, flower, capsule, tea, or another form
• how much THC and CBD it contains
• whether the terpene profile may be relevant
• whether the route has been verified for the way it is being used ^2,3,6,7

The older indica, sativa, and hybrid labels are increasingly seen as too blunt to guide clinical decision-making well. A Nature Plants study found those labels poorly captured overall genetic and chemical variation, while a 2025 paper on chemovars argued that terpene-based classification is more meaningful than the old sativa and indica model. ^6,7

For patients, the simple takeaway is this: your doctor is usually looking past the strain-style language and focusing on chemistry, form, safety, and fit. ^2,3,6,7

How clinicians choose a form

Good prescribing is not about picking a format in isolation.

It is about matching the format to the person. In practice, clinicians commonly think about:

• the symptom pattern and timing
• whether a slower or faster onset makes more sense
• whether the person needs a route that is easy to dose consistently
• whether THC needs to be minimised
• whether the product’s verified route matches the intended use
• other medicines and the possibility of interactions
• whether the person drives, does safety-sensitive work, or may face workplace drug testing
• how response and adverse effects will be monitored ^{1,2,3,4,5,11,12}

bpacnz’s treatment planning material is especially useful here. It recommends establishing treatment objectives, a timeframe, a dosing strategy, a risk management plan, monitoring criteria, and a discontinuation strategy. That is a good reminder that the route is only one part of a larger plan. ³

Practical notes patients often ask about

Onset and duration

Swallowed routes such as oils, capsules, and tea are usually slower and more variable. Oromucosal sprays sit somewhere in the middle. Vaporisation is faster and shorter-acting. ³

Convenience

Oils, capsules, and sprays are often easier to use discreetly. Tea requires preparation. Vaporisation may be less practical in some environments even if it suits the clinical goal. ^1,3

Driving

Driving comes up a lot, and for good reason.

New Zealand Police states that a medicinal cannabis product with high THC could be as impairing as recreational cannabis, that a person taking prescription medicine should follow the advice of their health practitioner, and that anyone experiencing impairing effects should not drive. ¹¹ BPACNZ also advises patients starting medicinal cannabis to avoid driving until it is clear how the product affects them, and notes that THC is more likely to impair cognitive function than CBD. ³

Workplace and testing considerations

WorkSafe says impairment at work can come from many causes, including drug use, fatigue, health conditions, noise, and stress. It also notes that some workplaces may use drug testing as one tool where impairment has been identified as a risk, although mandatory drug testing is not a prescribed legal requirement. ¹²

That is why the workplace conversation matters before starting treatment, especially if a person does safety-critical work or works under a strict alcohol and other drugs policy. ¹²

Forms of medicinal cannabis at a glance

Form	Main practical advantages	Main limitations	Clinical notes
Oil or oral liquid	Familiar route, easy to measure, discreet	Slow onset, variable absorption	Swallowed route with longer duration. Often easier for routine use. 1,3
Oromucosal spray	Practical for some people, more portable than tea	Still partly swallowed, technique matters	Often sits between a swallowed route and a purely oral-mucosal route. 3
Dried flower for vaporisation	Fast onset, shorter duration	Less practical in some settings, device requirements matter	Only suitable when flower is verified for inhalation via a vaporiser. 1,2,3
Dried flower for tea	Oral route, may suit some patients who prefer not to inhale	Preparation needed, slow and variable response	Only for flower verified for tea. Ministry provides generic tea instructions. 2,3
Capsules	Convenient, consistent format, discreet	Same slower swallowed route profile	Availability may be product-specific and can involve unapproved-medicine pathways. 1,3,4,5
Topicals	Local application may appeal to some patients	Onset and duration less predictable	Many international examples are CBD-based. NZ availability is product-specific and otherwise unspecified. 3,10

The bottom line

There is no single “best” way to use medicinal cannabis in New Zealand.

There are different delivery methods, and each one changes the clinical picture. That is why clinicians focus on route, formulation, cannabinoid balance, possible terpene profile, and day-to-day practicality rather than relying on strain names or internet shortcuts. ^1,2,3,6,7

If you are exploring medicinal cannabis, the delivery-method question is a good one to ask. It just works best when it sits inside a broader clinical conversation about what fits your situation, what needs monitoring, and what trade-offs actually matter to you. ³

References

1. Ministry of Health NZ. Information for consumers about medicinal cannabis. https://www.health.govt.nz/regulation-legislation/medicinal-cannabis/information-for-consumers
2. Ministry of Health NZ. Medicinal cannabis products that meet the minimum quality standard. https://www.health.govt.nz/regulation-legislation/medicinal-cannabis/information-for-health-professionals/minimum-quality-standard-medicinal-cannabis-products
3. bpacnz. An overview of medicinal cannabis for health practitioners. https://bpac.org.nz/2022/medicinal-cannabis.aspx
4. Medsafe. New Zealand Regulatory Guidelines for Medicines: Supplying Unapproved Medicines. https://medsafe.govt.nz/regulatory/Guideline/Full – NZ Regulatory Guidelines for Medicines.pdf
5. Medsafe Prescriber Update. Section 25 and the use of unapproved medicines. https://www.medsafe.govt.nz/profs/PUarticles/PDF/PrescriberUpdate_Jun05.pdf
6. Watts S, McElroy K, Migicovsky Z, et al. Cannabis labelling is associated with genetic variation in terpene synthase genes. Nature Plants. 2021. https://www.nature.com/articles/s41477-021-01003-y
7. Herwig N, Utgenannt S, Nickl F, et al. Classification of Cannabis Strains Based on their Chemical Fingerprint: A Broad Analysis of Chemovars in the German Market. Cannabis and Cannabinoid Research. 2025. https://doi.org/10.1089/can.2024.0127
8. Poyatos L, Pérez-Acevedo AP, Papaseit E, et al. Oral Administration of Cannabis and Delta-9-Tetrahydrocannabinol Preparations: A Systematic Review. Medicina. 2020;56(6):309. https://doi.org/10.3390/medicina56060309
9. Brunetti P, Pichini S, Pacifici R, Busardò FP, Del Rio A. Herbal Preparations of Medical Cannabis: A Vademecum for Prescribing Doctors. Medicina. 2020;56(5):237. https://doi.org/10.3390/medicina56050237
10. Scholfield CN, Kogan NM, Mechoulam R. Systematic Review on Transdermal and Topical Cannabidiol. Cannabis and Cannabinoid Research. 2023. https://doi.org/10.1089/can.2021.0154
11. New Zealand Police. Updates to drug driving legislation. https://www.police.govt.nz/advice-services/drugs-and-alcohol/updates-drug-driving-legislation
12. WorkSafe New Zealand. Impairment and testing for drugs at work. https://www.worksafe.govt.nz/laws-and-regulations/operational-policy-framework/worksafe-positions/impairment-and-testing-for-drugs-at-work/